Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR

While first line targeted therapies are the current standard of care treatment for non-small cell lung cancer (NSCLC) with actionable mutations, the cancer cells inevitably acquire resistance to these agents over time. Immune check-point inhibitors (ICIs) have improved the outcomes of metastatic NSC...

Full description

Bibliographic Details
Main Authors: Karan Seegobin, Umair Majeed, Nathaniel Wiest, Rami Manochakian, Yanyan Lou, Yujie Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-12-01
Series:Frontiers in Oncology
Subjects:
targeted mutations
immunotherapy
c-MET
RET
BRAF
ROS-1
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.750657/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.750657/full

Similar Items